HomeCompareSHTDY vs MRK

SHTDY vs MRK: Dividend Comparison 2026

SHTDY yields 3.61% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $34.8K in total portfolio value
10 years
SHTDY
SHTDY
● Live price
3.61%
Share price
$13.04
Annual div
$0.47
5Y div CAGR
-17.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.0K
Annual income
$59.46
Full SHTDY calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — SHTDY vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSHTDYMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SHTDY + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SHTDY pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SHTDY
Annual income on $10K today (after 15% tax)
$306.48/yr
After 10yr DRIP, annual income (after tax)
$50.54/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $8,277.87/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SHTDY + MRK for your $10,000?

SHTDY: 50%MRK: 50%
100% MRK50/50100% SHTDY
Portfolio after 10yr
$39.4K
Annual income
$4,928.80/yr
Blended yield
12.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SHTDY
No analyst data
Altman Z
3.9
Piotroski
7/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SHTDY buys
0
MRK buys
0
No recent congressional trades found for SHTDY or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSHTDYMRK
Forward yield3.61%2.76%
Annual dividend / share$0.47$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-17.4%32.7%
Portfolio after 10y$22.0K$56.8K
Annual income after 10y$59.46$9,798.13
Total dividends collected$1.5K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SHTDY vs MRK ($10,000, DRIP)

YearSHTDY PortfolioSHTDY Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,998$297.83$11,206$366.19$208.00MRK
2$12,021$252.85$12,650$502.35$629.00MRK
3$13,075$213.35$14,407$694.19$1.3KMRK
4$14,170$179.15$16,585$967.82$2.4KMRK
5$15,311$149.87$19,342$1,363.89$4.0KMRK
6$16,508$125.02$22,913$1,947.19$6.4KMRK
7$17,768$104.05$27,662$2,823.89$9.9KMRK
8$19,098$86.45$34,159$4,173.35$15.1KMRK
9$20,507$71.73$43,337$6,308.80$22.8KMRK
10$22,002$59.46$56,776$9,798.13$34.8KMRK

SHTDY vs MRK: Complete Analysis 2026

SHTDYStock

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.

Full SHTDY Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this SHTDY vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SHTDY vs SCHDSHTDY vs JEPISHTDY vs OSHTDY vs KOSHTDY vs MAINSHTDY vs JNJSHTDY vs ABBVSHTDY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.